| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | JAG1; AGS; AHD; AWS; HJ1; AGS1; JAGL1 |
| Entrez GeneID | 182 |
| clone | 6A9B2 |
| WB Predicted band size | 133.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD339 (AA: extra 47-212) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD339(Jagged1)抗体的模拟参考文献示例：
1. **文献名称**: *"Anti-Jagged1 Antibody Inhibits Notch Signaling and Reduces Tumor Growth in Triple-Negative Breast Cancer Models"*
**作者**: Smith A, et al.
**摘要**: 研究报道了一种靶向Jagged1的单克隆抗体，通过阻断Notch信号通路抑制三阴性乳腺癌细胞的增殖和肿瘤干细胞活性，显著延缓小鼠移植瘤生长。
2. **文献名称**: *"Development of a Humanized Anti-CD339 Antibody for Therapeutic Targeting of Notch Ligands in Autoimmune Diseases"*
**作者**: Chen L, et al.
**摘要**: 该文献描述了一种人源化抗CD339抗体的开发，通过体外和体内实验证明其可有效阻断Jagged1-Notch相互作用，减轻类风湿性关节炎模型中的炎症反应。
3. **文献名称**: *"Epitope Mapping of Anti-Jagged1 Antibodies Reveals Critical Domains for Notch Pathway Modulation"*
**作者**: Wang Y, et al.
**摘要**: 研究通过表位定位技术解析了不同抗CD339抗体与Jagged1蛋白的结合区域，揭示了其调控Notch信号的关键结构域，为优化治疗性抗体设计提供依据。
4. **文献名称**: *"Jagged1-Specific Antibody-Drug Conjugate Demonstrates Efficacy in Ovarian Cancer with Stromal Activation"*
**作者**: Rodriguez M, et al.
**摘要**: 研究构建了一种靶向Jagged1的抗体-药物偶联物(ADC)，在肿瘤基质高表达Jagged1的卵巢癌模型中显示出显著杀伤效果，提示其作为精准疗法的潜力。
(注：以上文献为模拟示例，实际引用需检索PubMed等数据库获取真实文献信息。)
CD339 antibody targets the CD339 antigen, also known as Jagged1. a cell surface protein belonging to the Notch ligand family. Jagged1 plays a critical role in the Notch signaling pathway, a highly conserved system regulating cell differentiation, proliferation, and apoptosis. It is expressed in various tissues, including endothelial, epithelial, and hematopoietic cells, and is involved in embryonic development, tissue homeostasis, and immune responses. Dysregulation of Jagged1-mediated Notch signaling has been implicated in cancers, cardiovascular diseases, and inflammatory disorders.
CD339 antibodies are widely used in research to study Notch pathway dynamics, particularly in tumor microenvironments where Jagged1 overexpression correlates with angiogenesis, metastasis, and drug resistance. These antibodies enable detection of Jagged1 expression via techniques like flow cytometry, immunohistochemistry, and Western blotting. Therapeutic applications are also emerging, with anti-Jagged1 antibodies explored for blocking Notch signaling in cancers (e.g., breast, leukemia) or modulating immune responses.
Developed as monoclonal or polyclonal reagents, CD339 antibodies vary in specificity, with some targeting extracellular domains for functional blocking or intracellular epitopes for signaling analysis. Validation remains essential due to pathway complexity and cross-reactivity risks. Overall, CD339 antibodies serve as vital tools for unraveling Jagged1's role in health and disease, bridging basic research and therapeutic innovation.
×
